Investigating Acetaminophen Toxicity Using Microfluidic Biochips
Author Information
Author(s): Jean Matthieu Prot, Anne-Sophie Briffaut, Franck Letourneur, Philippe Chafey, Franck Merlier, Yves Grandvalet, Cécile Legallais, Eric Leclerc
Primary Institution: Université de Technologie de Compiègne
Hypothesis
Can microfluidic biochips provide a more accurate model for studying acetaminophen toxicity compared to traditional Petri dish cultures?
Conclusion
The study found that microfluidic biochips better mimic in vivo conditions for assessing acetaminophen toxicity, showing significant differences in cell response compared to Petri dishes.
Supporting Evidence
- Microfluidic biochips showed a 50% growth inhibition of liver cells at 1 mM acetaminophen, similar to toxic levels in humans.
- Transcriptomic and proteomic analyses revealed the induction of the NRF2 pathway in biochip cultures.
- APAP conjugation activity was three times higher in biochips compared to Petri dishes.
- Cell cycle analysis indicated disrupted distribution in both culture systems due to APAP treatment.
Takeaway
Researchers used tiny chips to grow liver cells and found that these chips showed how a common painkiller can be toxic to the liver, much like it happens in real life.
Methodology
The study involved cultivating HepG2/C3A liver cells in microfluidic biochips and Petri dishes, followed by transcriptomic and proteomic analyses to assess the effects of acetaminophen.
Limitations
The study did not account for protein binding to acetaminophen, which may differ between in vivo and in vitro conditions.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website